Homburger advised BioVersys on the extension of its Series C fundraising round
On January 5, 2023, BioVersys announced that the AMR Action Fund has joined existing investors of BioVersys, extending the total proceeds of the Series C round to CHF 32.6 million. The Swiss pharma company represents the first European-based investment of the AMR Action Fund. The funds will go towards further trials of the pharmaceutical company’s assets.
BioVersys is a privately held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation. The company is a Venture Kick winner as well as a Venture Leaders alum. It ranked among the TOP 100 Swiss Startups from 2011 to 2013.
Homburger has advised BioVersys in this transaction. The legal team comprised partner Dieter Gericke (pictured left) and associate Thierry Burckhardt (pictured right; both Corporate / M&A).
